Portfolio concentration
As of April 30, 2026 · N-PORT
Holdings
149
Top-10 weight
29.94%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
48
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
504.9
Holdings
As of April 30, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | DREYFUS GOVT CASH MGMT FUND | DGCXX | 40,990,416 | $40.99M | 7.90% |
| 2 | GOLDMAN FINL SQ TRSRY INST 506 | — | 34,559,954 | $34.56M | 6.66% |
| 3 | US ULTRA BOND CBT Sep25 | — | 1 | $14.43M | 2.78% |
| 4 | GOLDMAN SACHS FIN GOV 465 INSTITUT | — | 9,422,419 | $9.42M | 1.82% |
| 5 | APELLIS PHARMACEUTICALS INC | — | 194,250 | $7.95M | 1.53% |
| 6 | US ULTRA BOND CBT Sep25 | — | 1 | $7.89M | 1.52% |
| 7 | REVOLUTION MEDICINES INC | — | 48,748 | $7.03M | 1.35% |
| 8 | TRAVERE THERAPEUTICS INC | — | 164,067 | $6.91M | 1.33% |
| 9 | ARROWHEAD PHARMACEUTICALS INC | — | 83,558 | $6.14M | 1.18% |
| 10 | TWIST BIOSCIENCE CORP | — | 103,603 | $6.06M | 1.17% |
| 11 | SUMMIT THERAPEUTICS INC | — | 278,847 | $5.98M | 1.15% |
| 12 | ALKERMES PLC | — | 174,823 | $5.89M | 1.14% |
| 13 | TG THERAPEUTICS INC | — | 173,080 | $5.85M | 1.13% |
| 14 | MADRIGAL PHARMACEUTICALS INC | — | 11,249 | $5.82M | 1.12% |
| 15 | US ULTRA BOND CBT Sep25 | — | 1 | $5.72M | 1.10% |
| 16 | BEAM THERAPEUTICS INC | — | 186,154 | $5.65M | 1.09% |
| 17 | APOGEE THERAPEUTICS INC | — | 65,006 | $5.39M | 1.04% |
| 18 | SCHOLAR ROCK HOLDING CORP | — | 112,425 | $5.24M | 1.01% |
| 19 | PRAXIS PRECISION MEDICINES INC | — | 16,345 | $5.21M | 1.00% |
| 20 | EXELIXIS INC | — | 116,281 | $5.17M | 1.00% |
| 21 | MIRUM PHARMACEUTICALS INC | — | 52,917 | $5.15M | 0.99% |
| 22 | US ULTRA BOND CBT Sep25 | — | 1 | $5.11M | 0.98% |
| 23 | UNITED THERAPEUTICS CORP DEL | — | 8,914 | $5.09M | 0.98% |
| 24 | NATERA INC | — | 24,696 | $5.09M | 0.98% |
| 25 | CELCUITY INC | — | 41,941 | $5.09M | 0.98% |
| 26 | CRISPR Therapeutics A.G. Series A | CRSP US | 97,235 | $5.09M | 0.98% |
| 27 | KRYSTAL BIOTECH INC | — | 19,037 | $4.99M | 0.96% |
| 28 | PROTAGONIST THERAPEUTICS INC | — | 50,321 | $4.98M | 0.96% |
| 29 | NEUROCRINE BIOSCIENCES INC | — | 37,476 | $4.93M | 0.95% |
| 30 | INCYTE CORP | — | 51,287 | $4.89M | 0.94% |
| 31 | CG ONCOLOGY INC | — | 73,170 | $4.88M | 0.94% |
| 32 | CYTOKINETICS INC | — | 76,297 | $4.88M | 0.94% |
| 33 | NUVALENT INC-A | — | 48,521 | $4.87M | 0.94% |
| 34 | IONIS PHARMACEUTICALS INC | — | 64,911 | $4.85M | 0.94% |
| 35 | BRIDGEBIO PHARMA INC | — | 68,003 | $4.84M | 0.93% |
| 36 | VAXCYTE INC | — | 84,388 | $4.83M | 0.93% |
| 37 | KYMERA THERAPEUTICS INC | — | 59,553 | $4.83M | 0.93% |
| 38 | BIOGEN INC | — | 25,484 | $4.82M | 0.93% |
| 39 | COGENT BIOSCIENCES INC | — | 134,554 | $4.82M | 0.93% |
| 40 | PTC THERAPEUTICS INC | — | 73,928 | $4.81M | 0.93% |
| 41 | INSMED INC | — | 34,830 | $4.75M | 0.92% |
| 42 | ALNYLAM PHARMACEUTICALS INC | — | 15,151 | $4.69M | 0.90% |
| 43 | ROIVANT SCIENCES | — | 164,121 | $4.68M | 0.90% |
| 44 | HALOZYME THERAPEUTICS INC | — | 73,023 | $4.65M | 0.90% |
| 45 | ARCUTIS BIOTHERAPEUTICS INC | — | 196,991 | $4.57M | 0.88% |
| 46 | SPYRE THERAPEUTICS INC | — | 61,270 | $4.56M | 0.88% |
| 47 | SOLENO THERAPEUTICS INC | — | 85,699 | $4.53M | 0.87% |
| 48 | ABBVIE INC | — | 21,322 | $4.51M | 0.87% |
| 49 | AMGEN INC | — | 12,853 | $4.45M | 0.86% |
| 50 | REGENERON PHARMACEUTICALS INC | — | 6,267 | $4.43M | 0.85% |
1 / 4
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.